Please use this identifier to cite or link to this item:
http://hdl.handle.net/11434/1383
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Pascoe, C. | - |
dc.contributor.author | Lawrentschuk, Nathan | - |
dc.contributor.other | Ow, Darren | - |
dc.contributor.other | Jack, Gregory | - |
dc.contributor.other | Perera, M. | - |
dc.contributor.other | Woo, Henry | - |
dc.date.accessioned | 2018-06-13T03:00:42Z | - |
dc.date.available | 2018-06-13T03:00:42Z | - |
dc.date.issued | 2018-02 | - |
dc.identifier.citation | BJU International. Conference: 71st Annual Scientific Meeting of the Urological Society of Australia and New Zealand, Feb 2018; 121(S1): 66 | en_US |
dc.identifier.uri | http://hdl.handle.net/11434/1383 | - |
dc.description.abstract | Introduction: Benign prostatic hyperplasia (BPH) is a common pathology causing lower urinary tract symptoms (LUTS) and may significantly impact quality of life. While transurethral resection of the prostate (TURP) remains the gold standard treatment, there are many evolving technologies that are gaining popularity. Photoselective vaporisation of the prostate (PVP) is one such therapy which has been shown to be non‐inferior to TURP. We aimed to review the literature and discuss factors to optimise patient outcomes in the setting of PVP for BPH. Methods: A comprehensive search of the electronic databases, including MEDLINE, Embase, Web of Science and The Cochrane Library was performed on articles published after the year 2000. MESH terms included; photoselective vaporisation of the prostate OR PVP, GreenLight laser, erectile function OR erectile dysfunction, BPH OR benign prostatic hyperplasia, outcome*, anti‐coagula* was performed. Search results were limited to those published in English, involving humans and published after the year 2000. Results: A total of 38 papers were included for review. It was found that the evolution of a higher powered device has enabled men with larger prostates and those on oral anticoagulation to undergo PVP safely and successfully. Despite continued oral anticoagulation in patients undergoing PVP, the risk of bleeding may be minimised with 5‐Alpha Reductase Inhibitor (5‐ARI) therapy however further studies are required. Pre treatment with 5‐ARI's does not hinder the procedure however more studies are required to demonstrate a reliable benefit. Current data suggests that success and complication rate is largely influenced by the experience of the operator. Post‐operative erectile dysfunction is reported in patients with previously normal function following PVP, however those with a degree of erectile dysfunction pre‐operatively may see improvement with alleviation of LUTS. Conclusion: There are multiple factors that may affect complication rate and patient outcomes following PVP, one of the largest being operator experience, however the procedure is safe and continues to evolve as a promising technology for BPH. | en_US |
dc.subject | Benign Prostatic Hyperplasia | en_US |
dc.subject | BPH | en_US |
dc.subject | Benign prostatic hyperplasia | en_US |
dc.subject | Lower Urinary Tract Symptoms | en_US |
dc.subject | LUTS | en_US |
dc.subject | Quality of Life | en_US |
dc.subject | QoL | en_US |
dc.subject | Transurethral Resection of the Prostate | en_US |
dc.subject | TURP | en_US |
dc.subject | Photoselective Vaporisation of the Prostate | en_US |
dc.subject | PVP | en_US |
dc.subject | Patient Outcomes | en_US |
dc.subject | Erectile Dysfunction | en_US |
dc.subject | Complication Rate | en_US |
dc.subject | UroRenal, Vascular Clinical Institute, Epworth HealthCare, Victoria, Australia | en_US |
dc.title | Photoselective vaporisation of the prostate (PVP)-patient selection and outcome optimisation. | en_US |
dc.type | Conference Poster | en_US |
dc.identifier.doi | 10.1111/bju.14117 | en_US |
dc.description.affiliates | Epworth Healthcare, Melbourne, Victoria, Australia; †Austin Hospital, Melbourne, Victoria, Australia | en_US |
dc.description.affiliates | Sydney Adventist Hospital Clinical School, Wahroonga, New South Wales, Australia | en_US |
dc.type.studyortrial | Literature Review | en_US |
dc.description.conferencename | The Urological Society of Australia and New Zealand 71st Annual Scientific Meeting, 24-27 February 2018 | en_US |
dc.description.conferencelocation | Melbourne, Australia | en_US |
dc.type.contenttype | Text | en_US |
Appears in Collections: | Epworth Prostate Centre |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Pascoe et al 2018.pdf | 821.99 kB | Adobe PDF | View/Open |
Items in Epworth are protected by copyright, with all rights reserved, unless otherwise indicated.